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Abstract
Objective To evaluate the intraocular pressure (IOP)-lowering efficacy and safety of 10 and 15 µg bimatoprost implant in 
patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Methods This randomized, 20-month, multicenter, masked, parallel-group, phase 3 trial enrolled 528 patients with OAG 
or OHT and an open iridocorneal angle inferiorly in the study eye. Study eyes were administered 10 or 15 µg bimatoprost 
implant on day 1, week 16, and week 32, or twice-daily topical timolol maleate 0.5%. Primary endpoints were IOP and IOP 
change from baseline through week 12. Safety measures included treatment-emergent adverse events (TEAEs) and corneal 
endothelial cell density (CECD).
Results Both 10 and 15 µg bimatoprost implant met the primary endpoint of noninferiority to timolol in IOP lowering 
through 12 weeks. Mean IOP reductions from baseline ranged from 6.2–7.4, 6.5–7.8, and 6.1–6.7 mmHg through week 12 
in the 10 µg implant, 15 µg implant, and timolol groups, respectively. IOP lowering was similar after the second and third 
implant administrations. Probabilities of requiring no IOP-lowering treatment for 1 year after the third administration were 
77.5% (10 µg implant) and 79.0% (15 µg implant). The most common TEAE was conjunctival hyperemia, typically tem-
porally associated with the administration procedure. Corneal TEAEs of interest (primarily corneal endothelial cell loss, 
corneal edema, and corneal touch) were more frequent with the 15 than the 10 µg implant and generally were reported after 
repeated administrations. Loss in mean CECD from baseline to month 20 was ~ 5% in 10 µg implant-treated eyes and ~ 1% 
in topical timolol-treated eyes. Visual field progression (change in the mean deviation from baseline) was reduced in the 10 
µg implant group compared with the timolol group.
Conclusions The results corroborated the previous phase 3 study of the bimatoprost implant. The bimatoprost implant met 
the primary endpoint and effectively lowered IOP. The majority of patients required no additional treatment for 12 months 
after the third administration. The benefit-risk assessment favored the 10 over the 15 µg implant. Studies evaluating other 
administration regimens with reduced risk of corneal events are ongoing. The bimatoprost implant has the potential to 
improve adherence and reduce treatment burden in glaucoma.
Clinicaltrials.gov Identifier NCT02250651.
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1 Introduction
Glaucoma is a disease characterized by optic nerve damage 
and vision loss. It has been estimated to affect 76 million 
individuals aged 40–80 years [1] and is the leading cause of 
irreversible blindness [2]. The most common form of glau-
coma is open-angle glaucoma (OAG), a chronic, progressive 
disease [3, 4]. The primary modifiable risk factor for glau-
coma is intraocular pressure (IOP). There is abundant evi-
dence that lowering IOP reduces the risk of development of 
glaucoma in individuals with ocular hypertension (OHT) as 
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Key Points 
The intracameral, sustained-release bimatoprost implant 
effectively lowered intraocular pressure in patients with 
open-angle glaucoma and ocular hypertension.
The effects of the implant on intraocular pressure were 
sustained beyond the expected duration of intraocular 
drug bioavailability.
The benefit/risk profile was most favorable for the 10 µg 
dose strength.
administration of daily topical eye drops [22]. This 
small, rod-shaped, biodegradable implant contains 10 µg 
bimatoprost in a drug delivery system consisting of poly-
mers similar to those used in biodegradable sutures [23]. 
The implant is administered intracamerally with a single-
use, prefilled 28-gauge applicator system [22] and pro-
vides slow, steady release of bimatoprost to reduce IOP 
as the polymer matrix is biodegraded through hydrolysis 
and metabolism to carbon dioxide and water [23, 24]. 
The implant was designed to release drug for 3–4 months. 
Drug release from the implant is complete within 90 days 
in vitro, and an in vivo study using beagle dogs admin-
istered a 15 µg implant similarly showed complete drug 
release and intraocular tissue drug levels below the limit 
of detection by 4.2 months after implant administration 
[23]. A drug-distribution study using beagle dogs fur-
ther showed that drug concentrations achieved in the 
iris-ciliary body (a target tissue for IOP lowering) were 
4400-fold higher after intracameral administration of 
a 15 µg bimatoprost implant than after 7 days of daily 
application of bimatoprost 0.03% eye drops [25]. In con-
trast, drug distribution to the bulbar conjunctiva, eye-
lid margins, and periorbital fat (tissues associated with 
topical PGA-related side effects) was below detectable 
levels or limited after bimatoprost implant administration 
compared with topical dosing [25]. These results suggest 
that targeted drug delivery with the intracameral bimato-
prost implant has the potential to minimize periorbital 
and ocular surface adverse effects associated with topical 
PGA administration.
Two phase 3 studies to fulfill US Food and Drug 
Administration (FDA) registration requirements evalu-
ated the efficacy and safety of bimatoprost implant 10 
µg and 15 µg compared with twice-daily topical timolol 
in lowering IOP in patients with OAG or OHT after ini-
tial and repeated administrations. The ARTEMIS 1 study 
results were reported previously [23] and showed that 
both dose strengths of bimatoprost implant were nonin-
ferior to timolol drops in lowering IOP. IOP lowering was 
sustained in most patients beyond the expected duration 
of intraocular drug bioavailability predicted by results of 
the pharmacokinetics studies in vitro and in animals, as 
well as by findings that drug concentrations in aqueous 
humor samples taken from two subjects during the study 
were below the limit of quantitation at 3–4 months after 
their last implant administration [23]. The benefit/risk 
profile favored the 10 µg implant over the 15 µg implant 
[23].
well as the risk of progression of glaucomatous optic nerve 
damage and vision loss [5–9]. Therefore, all approved treat-
ment modalities in glaucoma, whether pharmacological or 
surgical, aim to lower IOP.
Initial therapy for OAG and OHT is typically pharma-
cologic. Eye drops containing topical ophthalmic solu-
tions of IOP-lowering medications, such as prostaglan-
din analogs/prostamides (PGAs) and beta-blockers, are 
usually instilled once or twice daily. The PGAs (e.g., 
bimatoprost, latanoprost, tafluprost, and travoprost) are 
widely used in first-line therapy because they are most 
efficacious in lowering IOP and are well tolerated and 
systemically safe [10, 11]. Adherence to treatment is 
critical in glaucoma, as nonadherence is associated with 
worse visual outcomes [12, 13]. However, poor adher-
ence to topical IOP-lowering therapy is endemic in glau-
coma patients [14]. A study of adherence, as measured by 
the medication possession ratio, in 1234 newly diagnosed 
and treated patients with primary OAG estimated that 
only 20% of patients had persistently good adherence 
through 1 year of treatment [15]. Another study using 
pharmacy claims data similarly reported that patients 
who filled prescriptions for a topical PGA had medica-
tion available for dosing on only 37% of the days in the 
year [16]. Barriers to adherence to topical IOP-lowering 
therapy include forgetfulness, difficulty in instilling 
the eye drops, need for frequent administration, lack of 
understanding of the disease, the cost of medications, and 
side effects [14, 17–21]. Therefore, there is a need for 
alternative treatment modalities to deliver IOP-lowering 
medication without the need for daily eye drops.
Bimatoprost implant (Durysta; Allergan, an AbbVie 
company, Dublin, Ireland) was developed to address 
the problem of lack of adherence in glaucoma by low-
ering IOP without the need for patient or caregiver 
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We report here the results of the ARTEMIS 2 study, 
which was identical in design and clinical hypothesis to 
ARTEMIS 1 but involved different sites and different 
patients and, therefore, was independent of the ARTEMIS 
1 study.
2  Methods
2.1  Study Design
This randomized, multicenter, subject- and efficacy eval-
uator-masked, parallel-group, active-controlled, 20-month 
phase 3 clinical trial (ARTEMIS 2, registered at Clinical-
Trials.gov with the identifier NCT02250651) evaluated the 
efficacy and safety of bimatoprost implants in compari-
son with topical timolol for lowering IOP in subjects with 
OAG or OHT. The study was conducted at 114 sites in 15 
countries (Argentina, Canada, Colombia, Czech Republic, 
Egypt, Germany, Italy, Malaysia, New Zealand, Singapore, 
South Africa, South Korea, Turkey, the UK, and the USA) 
in accordance with the International Conference on Har-
monization E6 guideline for Good Clinical Practice. An 
institutional review board or ethics committee approved the 
study at each site, and all patients provided written informed 
consent.
2.2  Patients
The primary inclusion criteria included age ≥ 18 years 
with a diagnosis of OAG or OHT in each eye and both eyes 
requiring IOP-lowering treatment; study eye baseline IOP 
in the range of 22–32 mmHg at hour 0 (8 am ± 1 h) and 
19–32 mmHg at hour 2 (2 h after hour 0); study eye inferior 
iridocorneal angle Shaffer grade of ≥ 3 on gonioscopy and 
peripheral anterior chamber depth of ≥ 1/2 corneal thickness 
by Van Herick estimation; and central corneal endothelial 
cell density (CECD) by specular microscopy of ≥ 1800 
cells/mm2 by automated analysis at screening, with CECD 
in both eyes confirmed as qualified by the central reading 
center (CRC; Doheny Image Reading Center, Los Angeles, 
CA, USA) by baseline.
The primary exclusion criteria included history of closed-
angle glaucoma or non-responsiveness to topical ophthalmic 
beta-blockers and/or PGAs; peripheral anterior synechiae in 
the inferior iridocorneal angle on gonioscopic examination 
at screening in either eye; history or evidence of complicated 
cataract surgery in the study eye; and any contraindication 
to beta-blocker therapy.
A complete listing of all patient eligibility criteria is pro-
vided in Online Supplementary Material (OSM), Resource 
1.
2.3  Visit Schedule
Study visits included screening and baseline visits; admin-
istration visits on day 1, week 16, and week 32; follow-up 
visits during the active treatment period at weeks 2, 6, 12, 
15, 18, 22, 28, 31, 34, 38, 44, 48, and 52; and visits dur-
ing an extended safety follow-up at months 14, 16, 18, and 
20 (Fig. 1). If there were no safety concerns, patients who 
received fewer than three administrations of the bimatoprost 
implant or the sham procedure could complete and exit the 
study 12 months after the last administration received.
2.4  Randomization, Intervention, and Masking
After the screening visit to determine patient eligibility, 
patients using IOP-lowering medications began a washout 
period of up to 42 days before the baseline visit. The mini-
mum washout period was 4 days for parasympathomimet-
ics and carbonic anhydrase inhibitors, 14 days for sympa-
thomimetics and alpha-adrenergic agonists, and 28 days for 
beta-adrenergic antagonists, prostaglandin analogs (PGAs), 
and fixed-combination medications. On day 1, subjects were 
randomized in a 1:1:1 ratio to one of three treatment groups: 
10 µg bimatoprost implant, 15 µg bimatoprost implant, or 
timolol. The randomization was stratified by baseline study 
eye hour 0 IOP of ≤ 25 or > 25 mmHg. The sponsor pro-
vided a computer-generated randomization scheme, and an 
automated interactive voice response system/interactive 
web response system was used to manage the treatment 
assignments.
If both eyes were eligible to be the study eye, the eye 
with the higher IOP at baseline, or the right eye (if both 
eyes had the same IOP) was selected as the study eye. On 
administration day visits, an implant was administered to 
study eyes in the bimatoprost implant groups, and for mask-
ing, a sham procedure was administered to study eyes in the 
timolol treatment group and all fellow eyes (OSM, Resource 
2). Eyes were prepared for intraocular injection using stand-
ard practice for an intraocular procedure, and a single-use, 
needled, prefilled applicator system was used to administer 
the bimatoprost implant intracamerally as described previ-
ously [23]. In the sham procedure, a needleless applicator 
was used to touch the cornea. The second and third admin-
istrations of the bimatoprost implant or the sham procedure 
could be withheld in the event of a safety concern.
Throughout the study, study eyes in the timolol group 
and all fellow eyes were treated with topical timolol maleate 
0.5% (timolol) twice daily (BID); study eyes in the bimato-
prost implant groups received vehicle eye drops BID for 
masking. Timolol and vehicle eye drops were provided in 
identically appearing masked bottles labeled for the eye of 
administration (“Left” or “Right”) and were administered by 
the patients at 8 am (± 1 h) and 8 pm (± 1 h) daily, beginning 
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in the evening on the day 1 administration visit. On the 
morning of subsequent study visits, the drops were admin-
istered at the study site after the hour 0 IOP measurement.
For all patients, use of rescue (nonstudy) IOP-lowering 
medication in either eye was allowed during the first 52 
weeks (after confirmation of IOP at a subsequent visit) if 
the investigator attested that it was required for safety rea-
sons because of inadequate IOP control. After the week 52 
visit, rescue was allowed in either eye if the investigator 
determined that the IOP was not adequately controlled at 
two consecutive visits. To maintain masking, patients in the 
bimatoprost implant groups who used rescue treatment only 
in the study eye received sham administrations in the study 
eye on any subsequent administration days. Any patient who 
used rescue treatment in both eyes discontinued use of all 
study-provided eye drops and received no further administra-
tions of bimatoprost implant or sham procedure in either eye.
All patients, as well as the site personnel who collected 
efficacy data, were masked to the treatment and study eye 
assignment.
2.5  Outcome Measures
The main efficacy outcome measure was IOP evaluated at 
hours 0 and 2 with Goldmann applanation tonometry using 
a 2-person, masked reading method. The primary endpoints 
were the study eye IOP at hours 0 and 2 at weeks 2, 6, and 
12, and the hour-matched IOP change from baseline in the 
study eye at hours 0 and 2 at week 12.
The main safety measures were treatment-emergent 
adverse events (TEAEs, defined as adverse events with onset 
or increased severity, or that became serious, on or after the 
first study treatment date); CECD on specular microscopy; 
central corneal thickness (CCT) evaluated with ultrasound 
(contact) pachymetry; biomicroscopy; gonioscopy with 
Fig. 1  Patient flow through the study. Adm administration, BID twice daily, Bim bimatoprost, pts patients
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bimatoprost implant assessment; ophthalmoscopy; and 
best-corrected visual acuity (BCVA). Corneal TEAEs of 
interest (corneal touch, endothelial cell loss, edema, opac-
ity, disorder, or thickening) and anterior segment inflam-
matory TEAEs of interest (iritis, anterior chamber cell, iris 
adhesions, anterior chamber flare, keratitis, uveitis, anterior 
chamber inflammation, iridocyclitis, and keratic precipi-
tates) were also evaluated. Visual fields were evaluated at 
baseline, weeks 28 and 52, and month 20.
2.6  Statistical Analysis
The statistical analyses used the final database lock from 
the completed study and were performed with SAS version 
9.4 software (SAS Institute Inc, Cary, NC, USA). Previous 
planned interim analyses used database locks at weeks 12 
and 52. All statistical tests were two-sided with an alpha 
level of 0.05. The analyses of IOP used observed values in 
the intent-to-treat patient population. To avoid confounding 
of the efficacy data, IOP measurements taken after initiation 
of use of a rescue IOP-lowering medication or procedure in 
an eye were excluded from analysis.
Analysis of the IOP primary endpoint used a mixed-
effect model for repeated measures (MMRM) with IOP 
as the response variable. The model used an unstructured 
covariance matrix for repeated measures and included fixed 
effects of treatment, timepoint (hours 0 and 2 at weeks 2, 
6, and 12), treatment-by-timepoint interaction, and baseline 
IOP stratification (≤ 25 and > 25 mmHg); the hour-matched 
baseline IOP and the timepoint-by-baseline hour-matched 
IOP interaction were included as covariates. The difference 
between the 10 or 15 µg bimatoprost implant and timolol 
(bimatoprost implant minus timolol) and the corresponding 
two-sided 95% confidence interval (CI) for each timepoint 
was derived from the MMRM model. Noninferiority of the 
bimatoprost implant to timolol was established if the upper 
limit of the 95% CI was ≤ 1.5 mmHg for all six timepoints. 
If noninferiority to timolol was established, the bimatoprost 
implant was to be declared clinically noninferior to timolol 
if the upper limit of the 95% CI was ≤ 1.0 mmHg for three 
or more timepoints. Noninferiority of the 15 µg implant 
was tested first, followed by noninferiority testing of the 
10 µg implant [23]. Superiority tests were performed after 
noninferiority was established. For patients who received 
repeat administration in the study eye, similar MMRM mod-
els were used to evaluate IOP after the second and third 
administration.
A similar MMRM approach was used to evaluate IOP 
change from baseline. The model included IOP hour-
matched change from baseline as the response variable, 
with noninferiority of the bimatoprost implant to timolol 
established if the 95% CI of the between-group difference 
was within a 1.5 mmHg noninferiority margin at both hours 
0 and 2 at week 12. Diurnal IOP and the number of patients 
who had used additional (rescue) IOP-lowering treatment in 
the study eye were summarized with descriptive statistics. 
Kaplan-Meier survival analyses evaluated the time to initial 
use of additional treatment in the study eye after the last 
administration, and for patients who received three admin-
istrations in the study eye, after the third administration. 
For these analyses, patients who did not use any additional 
treatment in the study eye were censored at their last visit.
Safety analyses by treatment group were based on the first 
study treatment actually received in the study eye. Results 
for fellow eyes were pooled across treatment groups. Rates 
of TEAEs were evaluated overall and by administration 
cycle (for patients who received the administration) and dur-
ing the extended safety follow-up period (for patients who 
received three administrations). Analysis of visual fields 
used the mean deviation (MD) from Humphrey perimetry 
and excluded data collected after use of rescue IOP-lowering 
medication. When appropriate, post hoc statistical com-
parisons among groups and for 10 and 15 µg bimatoprost 
implant versus timolol were performed using chi-square or 
Fisher exact tests for categorical variables and analysis of 
covariance or MMRM models for continuous variables.
The planned sample size of approximately 600 patients 
used for the ARTEMIS 1 study [23] was modified for the 
ARTEMIS 2 study after discussion with the FDA, because 
evaluation of masked study data suggested lower IOP vari-
ability and a lower rate of patient rescue or discontinua-
tion from the study during the primary efficacy period than 
had been assumed for the initial sample size calculation. 
Enrollment of approximately 510 patients (170 per treat-
ment group) was planned to provide 95% power to show 
noninferiority of the 15 μg bimatoprost implant to timolol 
and 84% power to show noninferiority of the 10 μg bimato-
prost implant to timolol using the updated estimate of IOP 
variability and estimates of between-group differences from 
a previous study [22], and assuming a study discontinuation 
or rescue rate of 5% within 12 weeks.
3  Results
Enrollment in the study began in December 2014, and the 
study was completed in May 2020. A total of 528 patients 
were enrolled in the study and randomly assigned to one of 
the three treatment groups. Baseline demographics and study 
eye characteristics were generally well balanced among the 
treatment groups (Table 1). However, by chance the propor-
tion of patients who were Black or African American was 
higher in the timolol group than in the bimatoprost implant 
groups (Table 1).
The mean age of the study population was 62.6 years; 
49.1% of the patients were male, 63.4% were White, and 
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70.8% were diagnosed with primary OAG in the study eye. 
Most of the patients had phakic eyes and required washout 
of previous topical IOP-lowering medication before study 
enrollment. The baseline mean diurnal IOP was 23.7, 23.9, 
and 23.9 mmHg in the 10 µg implant, 15 µg implant, and 
timolol groups, respectively. CECD was required to be at 
least 1800 cells/mm2 at study entry, and at baseline the mean 
CECD ranged from 2434 to 2488 cells/mm2 among the treat-
ment groups.
Figure 1 shows the flow of patients through the study. 
Completion rates for the 20-month study were high and 
comparable among the treatment groups. The study was 
Table 1  Baseline demographics and study eye characteristics (ITT population)
AA African American, BID twice daily, Bim bimatoprost implant, CECD central corneal endothelial cell density, IOP intraocular pressure, ITT 
intent-to-treat, OAG open-angle glaucoma, OHT ocular hypertension, SD standard deviation
a P value based on two-sample t test for continuous variables and chi-square test for categorical values









Bim 10 µg  
vs. timolol
P  Valuea
Bim 15 µg 
vs. timolol
Age, mean (SD), years 62.5 (12.7) 63.8 (10.7) 61.4 (12.4) 0.446 0.055
 Range 23–88 24–85 19–90
Gender, n (%) 0.831 0.749
 Male 86 (48.9) 85 (48.3) 88 (50.0)
 Female 90 (51.1) 91 (51.7) 88 (50.0)
Race, n (%) 0.078 0.036
 White 115 (65.3) 116 (65.9) 104 (59.1)
 Hispanic 22 (12.5) 27 (15.3) 21 (11.9)
 Black or AA 20 (11.4) 19 (10.8) 36 (20.5)
 Asian 11 (6.3) 6 (3.4) 13 (7.4)
 Other 8 (4.5) 8 (4.5) 2 (1.1)
Iris color, n (%) 0.968 0.136
 Brown 82 (46.6) 81 (46.0) 82 (46.6)
 Dark brown 30 (17.0) 16 (9.1) 31 (17.6)
 Blue 24 (13.6) 20 (11.4) 20 (11.4)
 Hazel 6 (3.4) 7 (4.0) 9 (5.1)
 Green 5 (2.8) 2 (1.1) 2 (1.1)
 Gray 0 4 (2.3) 1 (0.6)
 Green/brown 10 (5.7) 18 (10.2) 12 (6.8)
 Blue/brown 14 (8.0) 20 (11.4) 14 (8.0)
 Other 3 (1.7) 7 (4.0) 3 (1.7)
 Not reported 2 (1.1) 1 (0.6) 2 (1.1)
Diagnosis, n (%) 0.575 0.557
 OAG
  Primary 131 (74.4) 118 (67.0) 125 (71.0)
  Pigmentary 3 (1.7) 7 (4.0) 4 (2.3)
  Pseudoexfoliation 1 (0.6) 2 (1.1) 2 (1.1)
 OHT 41 (23.3) 49 (27.8) 45 (25.6)
Lens status > 0.999 0.295
 Phakic 135 (76.7) 143 (81.3) 135 (76.7)
 Pseudophakic 41 (23.3) 33 (18.8) 41 (23.3)
CECD, mean (SD), cells/mm2 2434.2 (310.8) 2487.7 (301.9) 2469.2 (352.4) 0.324 0.598
 Range 1824–3215 1811–3719 1698–3643
IOP, mean (SD), mmHg
 Hour 0 24.3 (2.4) 24.4 (2.5) 24.5 (2.5) 0.500 0.790
 Hour 2 23.2 (2.8) 23.4 (2.8) 23.4 (3.1) 0.533 0.943
 Diurnal 23.7 (2.5) 23.9 (2.4) 23.9 (2.5) 0.446 0.857
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completed by 90.9%, 89.2%, and 88.1% of patients in the 10 
µg implant, 15 µg implant, and timolol groups, respectively.
Study drug exposure was evaluated in the safety popula-
tion of all treated patients. In the 10 µg implant group, 152 
patients (86.9%) received three implant administrations, 13 
patients (7.4%) received two implant administrations, and 
ten patients (5.7%) received one implant administration. In 
the 15 µg implant group, 142 patients (80.7%) received three 
implant administrations, 20 patients (11.4%) received two 
implant administrations, and 14 patients (8.0%) received one 
implant administration.
On gonioscopy, the implants were typically observed in 
the inferior iridocorneal angle. Figure 2 shows the appear-
ance of implants on gonioscopy in a representative patient. 
The implants frequently swelled after administration as they 
became hydrated and degraded. After the first administration 
on day 1, investigators reported visible implant on gonios-
copy at week 12 in 96.5% (164/170) of study eyes in the 10 
µg implant group, and for implants with size assessments, 
46.4% (58/125) were reported to be 51–100% of initial size, 
whereas 26.4% (33/125) were reported to be 101–150% of 
initial size. In the 15 µg implant group, visible implant was 
reported in 98.8% (168/170) of study eyes at week 12, and 
for implants with size assessments, 38.1% (48/126) were 
reported to be 51–100% of initial size, whereas 47.6% 
(60/126) were reported to be 101–150% of initial size. At 
week 52, the implant administered on day 1 in both the 10 
and 15 µg treatment groups was typically reported to be 
no longer visible or was estimated to be less than 25% of 
its initial size. At the end of the extended safety follow-up 
(month 20), one or more visible implants were reported in 
88.4% (130/147) of study eyes in the 10 µg implant group 
and 89.1% (122/137) of study eyes in the 15 µg implant 
group, and implants from each administration typically 
were reported to be no longer visible or were estimated to 
be ≤ 25% of their initial size.
3.1  Primary Endpoints: Intraocular Pressure (IOP) 
Lowering Through Week 12
The mean IOP in study eyes was consistently lower with the 
10 and 15 µg bimatoprost implants compared with timo-
lol BID at hours 0 and 2 at weeks 2, 6, and 12 (Fig. 3a). 
Moreover, the mean change from baseline IOP in study 
eyes was consistently larger with the 10 and 15 µg bimato-
prost implants compared with timolol BID at hours 0 and 
2 at weeks 2, 6, and 12 (Fig. 4a). Both the 10 and 15 µg 
bimatoprost implants met the a priori criteria for statistical 
and clinical noninferiority to timolol BID; the upper limit 
of the 95% CI of the difference from timolol in mean IOP 
(Fig. 3b) and mean change from baseline IOP (Fig. 4b) was 
< 1 mmHg for each implant dose strength at both hours 0 
and 2 at weeks 2, 6, and 12. The upper limit of the 95% CI 
of the difference from timolol was < 0 mmHg, indicating 
superiority of the bimatoprost implant to timolol in mean 
IOP and mean change from baseline IOP, at one of the six 
time points for the 10 µg implant and four of the six time 
points for the 15 µg implant.
3.2  Efficacy After Repeated Administration
The bimatoprost implant provided similar IOP lowering after 
repeated administrations (OSM, Resource 3).
3.3  Efficacy Throughout the Study
The mean IOP in study eyes was reduced from baseline in 
each treatment group at all follow-up visits during the active 
treatment period of the study (OSM, Resource 4). At week 
52 (the end of the active treatment period), the percentage 
of patients who remained in the study and had not received 
Fig. 2  Gonioscopic photographs of the study eye iridocorneal angle 
in a representative patient in the 10 μg bimatoprost implant treatment 
group. Photographs were taken at week 2, week 52, and month 20. 
Implants #1, #2, and #3 were administered at day 1, week 16, and 
week 32, respectively
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rescue treatment in the study eye was 81.8% (144/176) in the 
10 µg implant group, 77.8% (137/176) in the 15 µg implant 
group, and 84.1% (148/176) in the timolol BID group. The 
week 52 mean (standard deviation (SD)) diurnal IOP in the 
study eye of these patients was 17.8 (3.8) mmHg in the 10 µg 
implant group, 17.1 (3.6) mmHg in the 15 µg implant group, 
and 17.2 (3.3) mmHg in the timolol BID group.
The mean IOP in study eyes remained controlled in each 
treatment group throughout the extended safety follow-up 
(OSM, Resource 4). In the bimatoprost implant groups, 
patients received their last administration no later than 8 
months into the study, whereas patients in the timolol group 
continued their daily treatment through month 20. The per-
centage of patients who reached month 20 without receiving 
rescue treatment in the study eye was 64.8% (114/176) in the 
10 µg implant group, 64.2% (113/176) in the 15 µg implant 
group, and 78.4% (138/176) in the timolol BID group. The 
mean (SD) diurnal IOP in the study eye of these patients at 
month 20 was 18.2 (4.0) mmHg in the 10 µg implant group, 
17.6 (3.5) mmHg in the 15 µg implant group, and 17.2 (3.4) 
mmHg in the timolol BID group.
Kaplan-Meier survival analysis evaluated time to use of 
rescue IOP-lowering treatment in the study eye (Fig. 5). The 
estimated probability of not requiring rescue treatment in the 
study eye for 1 year after the last administration was 73.7% 
in the 10 µg implant-treated eyes and 70.6% in the 15 µg 
implant-treated eyes (Fig. 5a). For patients who received 
three administrations, the estimated probability of not requir-
ing rescue treatment in the study eye for 1 year after the third 
administration was 77.5% in the 10 µg implant-treated eyes 
and 79.0% in the 15 µg implant-treated eyes (Fig. 5b).
3.4  Safety Outcomes
Overall rates of TEAEs in each treatment group are sum-
marized in Table 2. One or more TEAEs were reported in 
74.9%, 88.1%, and 70.5% of patients in the 10 µg implant, 
15 µg implant, and timolol groups, respectively. Treatment-
related TEAEs, almost all ocular, were reported in 48.0%, 
61.9%, and 20.8% of patients in the 10 µg implant, 15 µg 
implant, and timolol groups, respectively.
Fig. 3  Primary endpoint of mean IOP through week 12. a LS mean 
IOP in study eyes at hours 0 and 2 at weeks 2, 6, and 12. b The 95% 
CIs of the between-group differences show that both the 10 and 15 µg 
bimatoprost implants met the prespecified criteria for statistical and 
clinical noninferiority to timolol BID. BID twice daily, Bim bimato-
prost, CI confidence interval, IOP intraocular pressure, LS least-
squares
Fig. 4  Primary endpoint of mean change in IOP from baseline 
through week 12. a LS mean change in IOP from baseline in study 
eyes at hours 0 and 2 at weeks 2, 6, and 12. b The 95% CIs of the 
between-group differences show that both the 10 and 15 µg bimato-
prost implants met the prespecified criteria for statistical and clinical 
noninferiority to timolol BID. BID twice daily, Bim bimatoprost, CI 
confidence interval, IOP intraocular pressure, LS least-squares
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Fig. 5  Kaplan-Meier survival 
analysis of time to initial use of 
additional IOP-lowering treat-
ment in the study eye a after 
the last bimatoprost implant 
or sham administration and b 
after the third administration 
in patients who received three 
administrations. BID twice 
daily, IOP intraocular pressure
Table 2  Summary of treatment-emergent adverse events (safety population)
BID twice daily, Bim bimatoprost implant, TEAE treatment-emergent adverse event
a P value based on chi-square test or Fisher exact test (when any frequency was < 5)
b Death from tumor metastases (15 µg implant group) and complications of hip fracture (timolol group) considered to be unrelated to treatment
TEAE Overall Incidence, n (%) P  Valuea
Bim 10 µg  
vs. timolol
P  Valuea
Bim 15 µg 








Any TEAE 131 (74.9) 155 (88.1) 122 (70.5) 0.364 < 0.001
Any treatment-related TEAE 84 (48.0) 109 (61.9) 36 (20.8) < 0.001 < 0.001
 Ocular 84 (48.0) 109 (61.9) 35 (20.2) < 0.001 < 0.001
 Nonocular 3 (1.7) 5 (2.8) 2 (1.2) > 0.999 0.448
Any serious TEAE 22 (12.6) 36 (20.5) 16 (9.2) 0.320 0.003
 Ocular 6 (3.4) 13 (7.4) 0 0.030 < 0.001
 Nonocular 17 (9.7) 25 (14.2) 16 (9.2) 0.882 0.151
Deathb 0 1 (0.6) 1 (0.6) 0.497 > 0.999
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Ocular TEAEs in the study eye, listed in OSM, Resource 
5, were mostly mild or moderate in severity and were 
reported in 62.3%, 80.7%, and 48.0% of patients in the 10 
µg implant, 15 µg implant, and timolol groups, respectively. 
The most common of these TEAEs were conjunctival hyper-
emia, foreign body sensation, and conjunctival hemorrhage, 
which typically were reported within 2 days after the study 
treatment in association with the administration procedure 
(Table 3). The occurrence of conjunctival hyperemia and 
foreign body sensation within 2 days after the administra-
tion procedure was likely related to the use of povidone-
iodine solution in the sterile preparation for the procedure. 
The median duration of TEAEs in study eyes after the first 
administration was 12.5, 14, and 15 days for conjunctival 
hyperemia; 5, 2, and 3 days for foreign body sensation; and 
12, 15, and 15 days for conjunctival hemorrhage in the 10 µg 
implant, 15 µg implant, and timolol groups, respectively. Iris 
hyperpigmentation in the study eye was reported as a TEAE 
in five patients in both the 10 and the 15 µg bimatoprost 
implant groups. There were no TEAE reports of eyelash 
growth or periorbital fat atrophy in any treatment group.
Serious ocular TEAEs (all in the study eye) were reported 
more frequently in the 10 and 15 µg implant groups (3.4% 
and 7.4% of patients, respectively) than in the timolol group 
(no patients) (P = 0.030 and P < 0.001 vs. timolol, respec-
tively). In both bimatoprost implant groups, the most com-
mon study eye serious ocular TEAE was corneal endothelial 
cell loss (CECL). The incidence rates for corneal TEAEs of 
Table 3  Treatment-emergent ocular adverse events in study eyes by time of onset after bimatoprost implant or sham procedure administration
BID twice daily, TEAE treatment-emergent adverse event. All ocular TEAEs in study eyes that were reported in ≥ 2% of subjects in any treat-
ment group within 2 days or after 2 days following administration are listed
a Any ocular TEAE in the study eye
b P value for comparison of overall TEAE vs. timolol (chi-square test)

















Conjunctival hyperemia 36 (20.6) 56 (31.8) 16 (9.2) 23 (13.1) 39 (22.2) 5 (2.9)
Conjunctival hemorrhage 16 (9.1) 12 (6.8) 11 (6.4) 0 2 (1.1) 3 (1.7)
Foreign body sensation in eye 13 (7.4) 14 (8.0) 2 (1.2) 7 (4.0) 5 (2.8) 0
Eye pain 11 (6.3) 15 (8.5) 5 (2.9) 0 11 (6.3) 3 (1.7)
Photophobia 11 (6.3) 12 (6.8) 0 2 (1.1) 3 (1.7) 0
Eye irritation 7 (4.0) 7 (4.0) 3 (1.7) 3 (1.7) 5 (2.8) 4 (2.3)
Aqueous humor leakage 5 (2.9) 1 (0.6) 0 0 0 0
Punctate keratitis 5 (2.9) 8 (4.5) 2 (1.2) 3 (1.7) 6 (3.4) 5 (2.9)
Anterior chamber cell 4 (2.3) 6 (3.4) 1 (0.6) 4 (2.3) 6 (3.4) 0
Dry eye 4 (2.3) 9 (5.1) 4 (2.3) 8 (4.6) 9 (5.1) 3 (1.7)
Lacrimation increased 4 (2.3) 5 (2.8) 1 (0.6) 2 (1.1) 5 (2.8) 0
Vision blurred 4 (2.3) 4 (2.3) 0 5 (2.9) 3 (1.7) 1 (0.6)
Ocular discomfort 3 (1.7) 7 (4.0) 1 (0.6) 0 5 (2.8) 0
Iritis 2 (1.1) 3 (1.7) 0 7 (4.0) 6 (3.4) 0
Blepharitis 1 (0.6) 2 (1.1) 0 8 (4.6) 5 (2.8) 5 (2.9)
Vitreous detachment 1 (0.6) 0 0 2 (1.1) 4 (2.3) 1 (0.6)
Conjunctivitis allergic 0 1 (0.6) 0 5 (2.9) 2 (1.1) 2 (1.2)
Corneal edema 0 2 (1.1) 0 6 (3.4) 21 (11.9) 0
Corneal endothelial cell loss 0 0 0 14 (8.0) 45 (25.6) 1 (0.6)
Corneal touch 0 0 0 2 (1.1) 4 (2.3) 0
Erythema of eyelid 0 1 (0.6) 1 (0.6) 4 (2.3) 2 (1.1) 0
Intraocular pressure increased 0 2 (1.1) 1 (0.6) 14 (8.0) 15 (8.5) 5 (2.9)
Iris adhesions 0 0 0 4 (2.3) 3 (1.7) 0
Iris hyperpigmentation 0 0 0 5 (2.9) 5 (2.8) 0
Vitreous floaters 0 0 0 5 (2.9) 1 (0.6) 2 (1.2)
Overalla 77 (44.0) 95 (54.0) 42 (24.3) 84 (48.0) 119 (67.6) 60 (34.7)
P  valueb < 0.001 < 0.001 – 0.012 < 0.001 –
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interest (mainly CECL, corneal edema, and corneal touch) 
and inflammatory TEAEs of interest (mainly anterior cham-
ber cell and iritis) in study eyes were higher in the bimato-
prost implant groups than in the timolol group and were 
higher in the 15 µg implant group than in the 10 µg implant 
group. Corneal TEAEs of interest were most commonly 
reported after repeated administrations. In the 10 µg implant 
group, occurrence or worsening of CECL was reported in 
no patients after the first and second administrations, 3.8% 
(6/156) of patients after the third administration (through 
the end of the week 52 visit window), and 5.8% (9/155) of 
patients during the extended safety follow-up through month 
20. In the 15 µg implant group, occurrence or worsening of 
CECL was reported in 0.6% (1/176) of patients after the 
first administration, 4.2% (7/165) of patients after the second 
administration, 11.6% (17/147) of patients after the third 
administration, and 14.6% (21/144) of patients during the 
extended safety follow-up through month 20.
Implants were removed because of a TEAE, most com-
monly corneal edema or CECL, in five patients (2.9%) in 
the 10 µg implant group and 19 patients (10.8%) in the 15 
µg implant group. The removal of implants was after the 
first, second, and third administrations, respectively, in one, 
one, and three patients in the 10 µg group and none, four, 
and 15 patients in the 15 µg group. The TEAE leading to 
the single implant removal after the first administration (in 
the 10 µg implant group) was “product administered at an 
inappropriate site” (the implant was accidentally injected 
into the corneal stroma). An additional patient in the 10 µg 
implant group underwent implant removal after the second 
administration because the implant resided in the injection 
track at the cornea.
Evaluation of CECD on specular microscopy showed a 
time-dependent loss of CECD in study eyes in the bimato-
prost implant groups, with greater loss in the 15 µg implant 
group (Table  4). At month 20, the mean CECD was 
approximately 5% lower than the baseline value for study 
eyes in the 10 µg implant group compared with approxi-
mately 1% lower than the baseline value for study eyes in the 
timolol BID group and for all fellow eyes treated with timo-
lol BID (Fig. 6). The proportion of study eyes with a ≥ 20% 
decrease in CECD from baseline in the 10 µg implant, 15 
µg implant, and timolol BID groups, respectively, was 0% 
(0/163), 1.2% (2/166), and 0% (0/156) at 12 weeks after the 
first administration (week 12), 0.6% (1/155), 3.9% (6/154), 
and 0% (0/159) at 12 weeks after the second administration 
(week 28), 3.5% (5/143), 10.3% (14/136), and 0% (0/146) 
at 12 weeks after the third administration (week 44), 5.3% 
(8/150), 15.4% (21/136), and 1.3% (2/152) at the end of the 
active treatment period (week 52), and 8.1% (14/173), 24.4% 
(43/176), and 0.6% (1/173) at month 20 or the last study 
visit before exit.
The mean BCVA for all study eyes and for study eyes 
with a corneal TEAE of interest was stable from baseline 
to the last available visit in each treatment group (Table 5). 
Among eyes with a corneal TEAE of interest, none in the 
10 µg implant group and two in the 15 µg implant group had 
a greater than two-line loss in BCVA from baseline at their 
last study visit (Table 5). Also, in each treatment group, 
mean changes from baseline in the study eye CCT at each 
visit were small and not considered to be clinically signifi-
cant. Among patients with a report of a corneal TEAE of 
interest, the study eye mean change in CCT from baseline 
at the last available visit was + 1.6 µm (n = 19), + 4.5 µm 
(n = 55), and + 28 µm (n = 1) in the 10 µg implant, 15 µg 
implant, and timolol groups, respectively.
At baseline, the mean (SD) MD in study eyes was − 2.21 
(4.01), − 1.56 (3.19), and − 1.78 (5.80) dB in the 10 µg 
implant, 15 µg implant, and timolol groups, respectively. 
Analysis of the change in the MD from baseline during the 
study showed progression of visual field loss in the timolol 
group; the progression of visual field loss was similar or 
Table 4  Mean (standard deviation) central corneal endothelial cell density in study eyes by specular microscopy, cells/mm2 (safety population)
BID twice daily, Bim bimatoprost implant
a P values are based on a mixed-effect model for repeated measures including treatment, visit, treatment-by-visit interaction, baseline central cor-









All fellow eyes  
(n = 524)
P  Valuea
Bim 10 µg  
vs. Timolol
P  Valuea
Bim 15 µg 
vs. Timolol
Baseline 2435.6 (311.2) 2487.7 (301.9) 2469.2 (355.1) 2437.1 (346.2) – –
Week 12 2425.4 (319.4) 2462.0 (310.8) 2448.8 (343.5) 2428.7 (359.4) 0.027 0.791
Week 28 2411.2 (327.3) 2411.5 (354.5) 2453.9 (355.3) 2427.4 (361.5) 0.280 < 0.001
Week 44 2382.9 (366.9) 2309.6 (504.0) 2461.2 (361.6) 2431.0 (372.3) 0.188 < 0.001
Week 52 2355.0 (404.0) 2237.9 (557.5) 2437.1 (372.6) 2420.1 (375.5) 0.059 < 0.001
Month 20 2303.6 (454.1) 2091.6 (638.9) 2451.5 (375.5) 2418.1 (369.8) 0.001 < 0.001
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reduced (P ≤ 0.037 vs. timolol at week 52) in the bimatoprost 
implant groups (Fig. 7). The mean change in MD from base-
line was − 0.08, − 0.26, and − 0.96 dB at week 52 and − 0.37, 
− 0.60, and − 1.18 dB at month 20 in the 10 µg implant, 15 µg 
implant, and timolol groups, respectively (Fig. 7).
4  Discussion
In this study, both the 10 and 15 µg bimatoprost implants 
were noninferior to topical timolol in lowering IOP through 
12 weeks. The study design included three administrations 
of implant at a fixed 4-month dosing interval, and efficacy 
after the second and third administrations was similar. 
Both dose strengths of implant provided IOP control in 
Fig. 6  Mean CECD in study 
eyes in the 10 µg bimatoprost 
implant and timolol treatment 
groups. The timing of implant 
or sham administration is shown 
with arrows. Statistical com-
parisons are reported in Table 4. 
BID twice daily, Bim bimato-
prost, BL baseline, CECD 
corneal endothelial cell density, 
M month, SEM standard error 
of the mean, W week
Table 5  Best-corrected visual acuity in study eyes
BCVA best-corrected visual acuity, BID twice daily, Bim bimatoprost implant, SD standard deviation, TEAE treatment-emergent adverse event
a All patients with a TEAE report of corneal endothelial cell loss, corneal edema, corneal opacity, corneal touch, corneal disorder, or corneal 
thickening who had a baseline BCVA assessment
b P value based on an analysis of covariance model including treatment with baseline BCVA as the covariate
c P value based on Fisher exact test
Safety parameter All patients Patients with corneal TEAE of  interesta
Bimatoprost 
implant 10 µg (n 
= 175)
Bimatoprost 





Bim 10 µg 
vs. Timolol
P Value













 Baseline 82.7 (5.6) 81.7 (6.4) 82.2 (6.4) 84.5 (5.0) 82.5 (5.8) 80
 Month 20 or last 
visit
83.3 (5.9) 81.6 (6.9) 82.7 (7.0) 0.662b 0.193b 84.7 (6.3) 81.6 (6.5) 80
Patients with > 
two-line (ten-
letter) loss in 
BCVA from 
baseline at 
month 20 or last 
visit, n (%)
2 (1.1) 5 (2.8) 3 (1.7) 0.684c 0.723c 0 2 (3.6) 0
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most patients for 1 year after the last implant administra-
tion without any additional IOP-lowering treatment. With 
the 4-month fixed-dosing interval used, the 10 µg implant 
demonstrated a better corneal safety profile than the 15 µg 
implant, presumably related to its smaller size. Both dose 
strengths of implant are cylindrical in shape with the same 
diameter, but the 15 µg implant is 50% longer than the 10 
µg implant.
The results of the ARTEMIS 2 study essentially rep-
licated those of the ARTEMIS 1 study. This is a positive 
finding for this novel treatment, as it provides an additional 
dataset with consistent results that clinicians can use to 
understand the efficacy and safety of the implant. In addi-
tion, the replication of the results in a second study, at dif-
ferent sites, reduces any potential bias.
One notable difference between the two ARTEMIS stud-
ies was that the ARTEMIS 2 study was planned to enroll 
fewer patients than ARTEMIS 1. However, the ARTEMIS 2 
study still was adequately powered, and both dose strengths 
of implant met the primary endpoint of noninferiority to 
topical timolol in lowering IOP. A difference in patient dis-
position was also evident between the two studies: in the 
ARTEMIS 1 study, the study completion rate was compa-
rable in the 10 µg implant and timolol groups and lower in 
the 15 µg implant group, whereas in the ARTEMIS 2 study, 
study completion rates were similarly high (approximately 
90%) across all treatment groups. The reason for this differ-
ence in results between the two studies is unknown.
The most common TEAEs (conjunctival hyperemia, con-
junctival hemorrhage, and foreign body sensation) typically 
occurred within 2 days after administration and were related 
to the administration procedure. Some of these events were 
likely caused by the procedure preparation, which included 
povidone-iodine irrigation. There were no reports of eyelash 
growth or periorbital fat atrophy, consistent with the findings 
of the ARTEMIS 1 study and a drug distribution study in 
dogs [25]. These results suggest that targeted drug delivery 
with the bimatoprost implant may be successful in reduc-
ing periocular adverse effects associated with topical PGAs. 
Anterior segment TEAEs of interest (most commonly iritis 
and anterior chamber cells) occurred in some patients in the 
bimatoprost implant groups. These TEAEs were typically 
mild in severity and transient. The TEAEs of most clinical 
concern were the corneal AEs reported in the bimatoprost 
implant groups. The frequency of these TEAEs was higher 
with the larger (15 µg) implant and after repeated adminis-
tration, consistent with the premise that the corneal TEAEs 
result from a physical interaction between the cornea and 
implants [23]. As many as three implants were present in the 
angle at the same time because of the slow rate of implant 
biodegradation and the 16-week fixed-interval administra-
tion schedule used in the study. There were no TEAE reports 
of CECL in patients after the first or second administration 
of the 10 µg implant. However, when multiple implants were 
administered at 4-month intervals, the CECD was decreased 
compared with timolol, and the difference between the 10 
µg implant and timolol became statistically significant at 
20 months.
The analysis of time to rescue demonstrated an extended 
duration of efficacy of the bimatoprost implant, with high 
probability (> 70%) of patients requiring no rescue for 1 
year after the third or last administration. These results are 
consistent with those of the ARTEMIS 1 study [23] and 
the previous 2-year, phase 1/2 dose-ranging study of the 
bimatoprost implant in patients with OAG (APOLLO) [26]. 
In the phase 1/2 study, 68%, 40%, and 28% of study eyes that 
received bimatoprost implant 6, 10, 15, or 20 µg (two 10 µg 
implants) on day 1 were controlled without any additional 
treatment up to months 6, 12, and 24, respectively [26].
As pharmacokinetics data for the bimatoprost implant 
(from drug distribution studies in dogs and aqueous sam-
ples after implant administration in humans) show that 
drug release is complete within 3–4 months [23], contin-
ued drug presence is unlikely to account for the sustained 
IOP lowering observed for 1 year or longer after implant 
administration. Matrix metalloproteinase (MMP)-induced 
durable tissue remodeling of aqueous outflow pathways 
has been proposed as a more likely explanation for the 
extended duration of IOP lowering after bimatoprost implant 
Fig. 7  Mean change in the visual field MD from baseline by Hum-
phrey perimetry in study eyes. Test results from eyes that had 
received rescue IOP-lowering treatment were excluded from the anal-
ysis. The number of eyes included in the analysis of change in MD 
from baseline at visits from week 28 to month 20 ranged from 101 to 
143 in the 10 µg bimatoprost implant group, 102 to 143 in the 15 µg 
bimatoprost implant group, and 123 to 144 in the timolol BID group. 
*P ≤ 0.037 vs. timolol based on a mixed-effect model for repeated 
measures including treatment, visit, treatment-by-visit interaction, 
baseline MD, and visit-by-baseline interaction. BID twice daily, BL 
baseline, IOP intraocular pressure, MD mean deviation, SEM stand-
ard error of the mean
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administration [23, 26–28]. Topical PGAs reduce IOP by 
inducing a concentration-dependent upregulation of MMP 
expression and activity in the ciliary body and trabecular 
meshwork, which leads to increased extracellular matrix 
turnover and tissue remodeling that decreases the resistance 
to aqueous outflow through the unconventional (uveoscleral) 
and conventional (trabecular meshwork) pathways [29–36]. 
The drug concentrations achieved in target tissues with the 
bimatoprost implant are orders of magnitude higher than 
those achieved with topical dosing [25], and these higher 
drug concentrations have been shown to produce much 
greater upregulation of MMPs in human ciliary body cell 
cultures [36]. The higher drug concentrations achieved in 
outflow tissues by the implant are proposed to produce a 
greater upregulation of MMPs, which causes a more durable 
tissue remodeling, leading to sustained IOP lowering [23, 
26–28].
The larger 15 µg bimatoprost implant was removed from 
subsequent development following the CECL observed in 
the ARTEMIS studies, but bimatoprost implant 10 µg has 
been approved by the FDA for single intracameral admin-
istration for the reduction of IOP in patients with OAG or 
OHT. The duration of effect demonstrated in the ARTEMIS 
and APOLLO studies suggests the potential for the bimato-
prost implant to effectively control IOP when used in treat-
ment regimens with long intervals between administrations. 
Ongoing studies (NCT03850782, NCT03891446) are evalu-
ating the safety and efficacy of as-needed administration of 
the implant.
By chance, there was an imbalance in race/ethnicity 
among treatment groups at randomization. We do not believe 
this imbalance in race/ethnicity was a confounding factor in 
the analyses, because a preplanned subgroup analysis of the 
pooled ARTEMIS 1 and ARTEMIS 2 study data (with larger 
sample size), which was performed for FDA drug approval, 
showed that overall IOP lowering was similar among racial/
ethnicity subgroups (FDA summary basis for approval sec-
tion 7.1.2). Another study limitation may have been the 
requirement for implant administrations at a fixed 4-month 
interval, because many patients may have had adequate IOP 
control and not needed repeated administrations. This issue 
is being addressed by the ongoing studies that are evaluating 
an as-needed dosing regimen. In addition, the Kaplan-Meier 
analysis was an indirect measure of the maintenance of the 
IOP-lowering effect over time. The decision of when to res-
cue was up to the investigator, and there were no defined IOP 
criteria for rescue.
A strength of this study was the collection and analysis 
of visual field MD data. Large population-based studies in 
treated patients with glaucoma have demonstrated worsen-
ing of the visual field over time, as assessed by the mean 
change in the visual field MD, with reported progression 
rates generally ranging from − 0.32 dB/year [37] to − 0.8 
dB/year [38]. Given these expected visual field progression 
rates, even with the current medical and surgical methods 
to treat glaucoma, the cumulative incidence of blindness in 
at least one eye among patients diagnosed with glaucoma 
and visual field loss was 26.5% after 10 years [39], which 
is unacceptable when life expectancies are increasing and 
patients are living longer with glaucoma [40]. The timolol 
group in our studies progressed − 0.97 dB in the first 12 
months, in the range of what is expected from other studies 
[41]. In contrast, the mean change in visual field MD from 
baseline over 1 year was − 0.08 dB for patients using the 
commercialized dose strength (10 µg) of the bimatoprost 
implant in the treatment regimen used in this study, demon-
strating stability of the visual field over time compared with 
timolol (Fig. 7).
Small changes in the visual field MD in patients with 
early glaucoma correspond to a significant loss of neural 
tissue, and patients with a mean MD of − 2 dB, as seen at 
baseline in this study, have already lost ~ 30% of their reti-
nal ganglion cells (RGCs) [42]. Based on the relationship 
between the MD and number of RGCs reported by Medeiros 
et al. [42], the difference of ~ 0.8 dB in change from base-
line MD at month 20 between the 10 µg implant-treated and 
timolol-treated eyes, which may appear small, corresponds 
to the preservation of an estimated 50,000 RGCs (~ 7%) 
with bimatoprost implant treatment compared with topical 
timolol treatment. These results suggest that with the treat-
ment regimen used in this study, the bimatoprost implant 
has the potential to preserve more RGCs and improve visual 
field preservation over time in patients with early glaucoma.
The reformulation of bimatoprost into a sustained-release 
implant has provided a novel, drop-free, drug-delivery 
option for glaucoma therapy. The implant addresses many 
barriers to adherence to topical therapy, and the continu-
ous drug release from the implant may potentially provide 
more stable 24/7 IOP control, leading to better preservation 
of the visual field. In many patients, intracameral delivery 
of bimatoprost with the implant may reduce the burden of 
treatment by providing long-term, sustained IOP control.
In summary, the efficacy and safety profiles of bimato-
prost implant that were demonstrated in this study repli-
cated those in the ARTEMIS 1 study, demonstrating that 
the results are robust. The implant effectively lowered IOP, 
and in many patients the IOP control provided by the implant 
persisted beyond the expected duration of intraocular drug 
bioavailability. The incidence of corneal TEAEs of inter-
est was higher in the bimatoprost implant groups than in 
the timolol group. The study used a fixed dosing regimen 
of three administrations at 16-week intervals, and with this 
dosing regimen, the smaller 10 µg implant had a better safety 
profile and benefit-risk ratio than the 15 µg implant. The 
results suggest a potential for bimatoprost implant treat-
ment to reduce the progression of visual field loss. Ongoing 
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studies are evaluating 24-h IOP control with the bimatoprost 
implant and the effects of the implant on the visual field. 
Studies are also in progress to understand ideal treatment 
intervals, given the unexpectedly long duration of action of 
the implant.
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